Evidence map›Paper›PMID 41222883›Full record

ArticleJournal of endocrinological investigation2026

The clinical challenge of MEN1 phenocopies: insights from a multicentric national retrospective study.

Rosaria M Ruggeri, Elio Benevento, Iderina Hasballa, Erika Maria Grossrubatscher, Roberta Modica, Manuela Albertelli, Bianca Golisano, Vito Guarnieri, Flavia Pugliese, Valentina Guarnotta and 8 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Rosaria M RuggeriDepartment of Human Pathology DETEV, Unit of Endocrinology, University of Messina, Messina, Italy.ORCID http://orcid.org/0000-0001-8899-684X
Elio BeneventoEndocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. elio.benevento@gmail.com.ORCID http://orcid.org/0000-0002-4489-3651
Iderina HasballaEndocrinology Unit, Department of Internal Medicine and Medical Specialties (DIMI), University of Genova, Genova, Italy. ihasballa@yahoo.com.ORCID http://orcid.org/0009-0003-7363-571X
Erika Maria GrossrubatscherEndocrine Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.ORCID http://orcid.org/0000-0001-7234-7618
Roberta ModicaEndocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.ORCID http://orcid.org/0000-0002-3768-5803
Manuela AlbertelliEndocrine Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.ORCID http://orcid.org/0000-0002-5957-3247
Bianca GolisanoEndocrinology Unit, Department of Clinical and Molecular Medicine, ENETS Center of Excellence, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
Vito GuarnieriDivision of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.ORCID http://orcid.org/0000-0002-5500-8558
Flavia PuglieseDivision of Medical Genetics, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.ORCID http://orcid.org/0000-0001-9968-8172
Valentina GuarnottaUnit of Endocrinology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, Policlinico Paolo Giaccone, Università degli studi di Palermo, Palermo, Italy.ORCID http://orcid.org/0000-0002-8088-4947
Simona JaafarUnit of Endocrinology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID http://orcid.org/0009-0002-6045-2992
Andrea LaniaUnit of Endocrinology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.ORCID http://orcid.org/0000-0002-5380-2141
Antonio PrinziEndocrinology Unit, Department of Clinical and Experimental Medicine, Medical Center, University of Catania, Catania, Garibaldi-Nesima, Italy.ORCID http://orcid.org/0009-0002-7021-9860
Isabella ZanataSection of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Maria Chiara ZatelliSection of Endocrinology, Geriatrics and Internal Medicine, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.ORCID http://orcid.org/0000-0001-8408-7796
Annamaria ColaoEndocrinology, Diabetology and Andrology Unit, Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.ORCID http://orcid.org/0000-0003-4049-2559
Antongiulio FaggianoEndocrinology Unit, Department of Clinical and Molecular Medicine, ENETS Center of Excellence, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-9324-3946
NIKE Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder caused by MEN1 gene mutations, typically involving primary hyperparathyroidism (PHPT), pancreatic neuroendocrine tumors (PanNETs), and/or pituitary neuroendocrine tumors (PitNETs). However, 10-30% of patients with MEN1-like features lack identifiable MEN1 mutations and are classified as phenocopies. This retrospective multicenter study, conducted across 10 Italian referral centers, aimed to characterize the main clinical features of phenocopies. Among 240 patients evaluated for suspected MEN1 over five years, 175 (mean age 43.2 ± 19.7; 101 females) had genetically confirmed MEN1, while 65 (27%; mean age 59.9 ± 11.6; 44 females) were identified as phenocopies. Of these, 46 (70.7%) were also negative for CDKN1B mutations, confirming the rarity of MEN4. Phenocopies were diagnosed one to two decades later than MEN1 patients (p < 0.0001). PHPT was the most frequent manifestation in both groups (80% of phenocopies vs. 81% of MEN1), but tumor associations differed significantly between groups (p < 0.001): 41% of MEN1 patients showed the classic triad, compared to only 1% of phenocopies; PHPT with NETs was more common in MEN1 (32%), whereas PHPT with PitNETs occurred more often in phenocopies (54%), reflecting patterns of sporadic tumors. Notably, 11% of phenocopies had a first-degree relative with MEN1-related diseases, and 51% had a personal or family history of cancer. In conclusion, MEN1 phenocopies are relatively common and represent a clinical challenge. Given their distinct features and familial backgrounds, an extended genetic panel should be offered to these patients together with periodical screening of MEN1-related disease.

Indexed as

Hyperparathyroidism, PrimaryMultiple Endocrine Neoplasia Type 1Neuroendocrine TumorsPancreatic NeoplasmsPituitary NeoplasmsAdultAgedFemaleHumansItalyMaleMiddle AgedMutationPhenotypePrognosisProto-Oncogene ProteinsMEN1 protein, humanProto-Oncogene ProteinsGenetic analysisMultiple endocrine neoplasia type 1 (MEN1)Neuroendocrine tumorsPhenocopyPituitary adenomasPrimary hyperparathyroidism

Identifiers

PMID41222883
PMCPMC13017983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.